Traduction de «medicines known » (Néerlandais → Français) :

Tekturna/Rasilez is the only approved high blood pressure therapy in a new class of medicines known as direct renin inhibitors.
Rasilez/Tekturna est le seul traitement autorisé contre l’hypertension qui fait partie d’une nouvelle classe de médicaments connus sous le nom d’inhibiteurs directs de la rénine.

Tekturna/Rasilez (USD 290 million, +104% lc), the first in a new class of medicines known as direct renin inhibitors to treat high blood pressure, has been growing consistently since its launch in 2007 based on positive clinical data demonstrating its prolonged efficacy in lowering blood pressure for more than 24 hours and superiority in clinical trials over ramipril, a leading ACE inhibitor.
Rasilez/Tekturna (USD 290 millions, +104% en m. l.), est le premier d’une nouvelle classe de médicaments, les inhibiteurs directs de la rénine, traitant l’hypertension.

A growing number of patients are returning for treatment with this medicine, which is known as Reclast in the US and Aclasta in the rest of the world.
Un nombre grandissant de malades reviennent pour être traités avec ce médicament connu sous la marque Reclast aux Etats-Unis et Aclasta dans le reste du monde.

Thanks to the introduction of a proactive vigilance policy within the FAMHP via the PROACTIVE VIGILANCE spearhead, the safety profile of medicines and health products will be better known, thereby also promoting safer use of these products.
Thanks to the introduction of a proactive vigilance policy within the FAMHP via the PROACTIVE VIGILANCE spearhead, the safety profile of medicines and health products will be better known, thereby also promoting safer use of these products.